Does Ultragenyx (RARE) Shifting Into Small‑Cap Value Indices Recast Its Rare‑Disease Growth Story?

• On 27 June 2026, Ultragenyx Pharmaceutical Inc. (NasdaqGS:RARE) was removed from several Russell large- and mid-cap and growth indices and added to multiple Russell small-cap and value benchmarks, including the Russell 2000 Index and Russell 2000 Value Index.
• This shift signals a market reclassification of Ultragenyx toward smaller-cap, value-oriented benchmarks, which can alter its investor base composition and index-linked demand.
• We’ll now examine how Ultragenyx’s move into small-cap value indices could influence its existing investment narrative around rare disease growth.

This technology could replace computers: discover 30 stocks that are working to make quantum computing a reality.

Ultragenyx Pharmaceutical Investment Narrative Recap

To own Ultragenyx today, you need to believe its rare disease platform can turn multiple late stage programs into durable, high value commercial products while the company manages heavy losses and a short cash runway. The index shift into small cap value benchmarks does not change the key near term catalyst, which remains the paired FDA decisions for DTX401 and UX111 in August and September 2026, nor the central risk around persistent cash burn and potential dilution.

The most relevant recent announcement here is the April 2026 FDA acceptance of the UX111 BLA for Sanfilippo syndrome Type A, with a PDUFA date of 19 September 2026. Together with the August 2026 decision date for DTX401, these gene therapy filings sit at the heart of the investment case and will likely matter more to Ultragenyx’s long term outcomes than the shift from the Russell 1000 into Russell 2000 and value indices.

Yet while these developments are encouraging, investors should also be aware that Ultragenyx still faces...

Read the full narrative on Ultragenyx Pharmaceutical (it's free!)

Ultragenyx Pharmaceutical's narrative projects $1.3 billion revenue and $114.0 million earnings by 2029.

Uncover how Ultragenyx Pharmaceutical's forecasts yield a $52.05 fair value, a 70% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts, who were looking for revenue to reach about US$1.6 billion and earnings of roughly US$313 million by 2029, see the same index move and regulatory risk around UX111 very differently, which shows how widely views can diverge and why it can be useful to compare several perspectives before you decide how this latest development fits into your own thesis.

Explore 3 other fair value estimates on Ultragenyx Pharmaceutical - why the stock might be worth over 7x more than the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Ultragenyx Pharmaceutical research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Ultragenyx Pharmaceutical research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Ultragenyx Pharmaceutical's overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 30 best rare earth metal stocks of the very few that mine this essential strategic resource.
• Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.
• AI is about to change healthcare. These 41 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com